Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $8.24 Average PT from Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have earned a consensus rating of "Hold" from the nine brokerages that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $8.24.

ZNTL has been the subject of several research reports. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Wedbush reissued a "neutral" rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. UBS Group cut their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Finally, Wells Fargo & Company decreased their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Thursday, January 30th.

Zentalis Pharmaceuticals Stock Up 4.2%

Shares of Zentalis Pharmaceuticals stock traded up $0.05 during mid-day trading on Friday, reaching $1.25. 1,005,203 shares of the stock traded hands, compared to its average volume of 1,556,922. The stock has a market capitalization of $89.94 million, a PE ratio of -0.50 and a beta of 1.81. The business has a 50-day moving average of $1.34 and a 200 day moving average of $2.21. Zentalis Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $13.00.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, meeting the consensus estimate of ($0.67). On average, equities research analysts expect that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, Director Scott Dunseth Myers acquired 21,000 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was purchased at an average price of $1.40 per share, with a total value of $29,400.00. Following the transaction, the director now owns 281,192 shares of the company's stock, valued at approximately $393,668.80. This trade represents a 8.07% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.90% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Corton Capital Inc. purchased a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at $32,000. Captrust Financial Advisors purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter worth about $33,000. Prudential Financial Inc. acquired a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $39,000. Cerity Partners LLC purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $40,000. Finally, Vident Advisory LLC acquired a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $45,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.